The patents on semaglutide, the molecule behind Ozempic and Wegovy, are lapsing. Which means the same drug that costs $1,300 a month in the US is about to become available in India at a fraction of that price. Generic manufacturers are already sharpening their pencils. It is only a matter of time.
In many ways, this is genuinely good news. Access to breakthrough medicine should not be a privilege of the wealthy. These drugs have shown remarkable results in clinical settings, particularly for people dealing with severe obesity or type 2 diabetes, where lifestyle changes alone have not been sufficient. For those who genuinely need them, under proper medical supervision, they can be life-changing. The science behind them is serious, and the results in trials have been, by any measure, impressive.
But if you have lived in India long enough, you already know how this story of cheap, accessible, powerful medication tends to go.
We are a country that treats antibiotics like breath mints. Fever on day one? Azithromycin. Child has a cold? Amoxicillin. Most of us have taken a full antibiotic course prescribed by a pharmacist who last studied biology in 1987. We are now paying the price for that habit, quietly building a population of antibiotic-resistant bacteria that no longer takes our medicine seriously. The drug was never the problem. The casual, unsupervised use of it was.
Which brings me to GLP-1 drugs and why I think it is worth understanding them properly before they arrive at scale in India.
So what exactly is GLP-1?
GLP-1 stands for Glucagon-Like Peptide-1. Terrible name. Much better explanation.
When you eat, your gut releases a hormone called GLP-1. It does several things simultaneously. It tells your pancreas to release insulin. It tells your liver to stop dumping more glucose into the blood. It slows down how fast food moves from your stomach to your intestine. And crucially, it travels to your brain and says, " We are done here, you can stop eating now."
That last part is the big one. GLP-1 is your body's natural fullness signal.
The problem is that in many people with obesity or type 2 diabetes, this signal is weak, delayed, or simply ignored. The brain receives the message and politely files it in the bin.
What semaglutide does, and why it is different
GLP-1 drugs mimic this hormone artificially, but in a much stronger, longer-lasting way. The first generation of these drugs broke down in the body within minutes and required twice-daily injections. Semaglutide was engineered to last a week on a single injection. That was the breakthrough that changed everything.
Then came tirzepatide, branded as Mounjaro, which targets two hormones simultaneously and has shown weight loss results of 20 to 22 percent of body weight in trials. That is a number the pharmaceutical world had never seen from a drug before.
For people with severe obesity, type 2 diabetes, or significant cardiovascular risk, these numbers represent something genuinely meaningful. These are not lifestyle drugs for people who want to lose five kilos before a wedding. At their intended use, for the right patient, with proper monitoring, they represent a serious medical advance.
Where it gets complicated
Here is where I want to be careful, because the science is still evolving and ongoing studies are actively examining many of these questions.
When you lose weight, through any method, you do not lose only fat. You lose a combination of fat and lean mass, which includes muscle, organ tissue, and bone density. The ratio depends heavily on how the weight is lost. Studies on semaglutide suggest that a meaningful portion of the weight lost can be lean mass, and researchers are actively studying how to minimise this through protein intake and resistance training alongside the medication.
Why does this happen? Your body, when faced with a sudden large caloric deficit, does not know you have taken a drug. From its perspective, food has become scarce. And in famine mode, it tends to preserve fat as the long term emergency reserve and break down muscle for immediate energy, a process called gluconeogenesis. Add to this that appetite is suppressed across the board, so protein intake drops along with everything else. And muscle, it turns out, is the body's first port of call when amino acids are needed for critical functions like immune repair and enzyme production.
There is also a hormonal dimension to this that does not get discussed enough.
IGF-1, or Insulin-like Growth Factor 1, is one of the primary drivers of muscle protein synthesis. It signals the body to build and repair muscle tissue. Under significant caloric restriction, IGF-1 levels drop. At the same time, cortisol, which is catabolic and actively breaks down muscle, tends to rise when the body perceives scarcity. So you end up with less of the hormone telling your body to build, and more of the hormone telling it to break down. The result is not surprising.
Now here is the part that deserves particular attention, especially for anyone considering these drugs after the age of 40 or 45. Muscle loss at that stage of life is not simply a fitness inconvenience. After a certain age, the body's capacity to rebuild lost muscle diminishes significantly. The anabolic machinery slows. You can slow the loss with effort, but replacing what is gone becomes genuinely difficult. For practical purposes, some of that muscle loss may be permanent.
And muscle is not just about strength or appearance. It is one of the primary sites where your body processes glucose. More muscle means better insulin sensitivity, lower blood sugar, and lower metabolic risk. Lose it, and you have quietly dismantled some of the most important infrastructure your metabolism runs on.
The same concern applies to bone. Bone density responds to mechanical load and hormonal signals. Rapid weight loss reduces the load your skeleton carries, which reduces the signal to maintain density. Combined with lower overall nutrient intake and, in older adults, already declining levels of estrogen and testosterone, bone remodelling can slow in ways that are not easy to reverse. Bone lost in this window may not come back fully either.
Not all fat is the same, and that matters
This is something most people do not know, and it changes the picture considerably.
Visceral fat, the dangerous kind packed around your organs, is associated with inflammation, insulin resistance, and cardiovascular disease. Reducing it is genuinely beneficial, and GLP-1 drugs do appear to target it. Good.
But there is also subcutaneous fat, which sits under the skin and is significantly less harmful. And then there is brown adipose tissue, which is actually metabolically active. It burns calories to generate heat, responds to insulin, and plays a useful role in metabolic regulation. The body under aggressive caloric restriction does not always distinguish neatly between these types. It tends to take from wherever is accessible.
More importantly, fat tissue is not just storage. Healthy fat cells, particularly subcutaneous fat, produce a hormone called adiponectin, which improves insulin sensitivity, reduces inflammation, and has a protective effect on the cardiovascular system. Lose significant fat rapidly and non-selectively, and you may also be reducing your capacity to produce it.
There is also leptin, a hormone produced by fat cells that signals satiety to the brain. It is one of the key regulators of long-term energy balance. GLP-1 drugs work partly by overriding this system artificially. What we do not yet fully understand is what sustained suppression of these natural hormonal signals means over the years. The long-term studies are still running. The ten-year data is not in. The medical community is watching carefully and drawing conclusions cautiously, which is exactly as it should be.
The dependency question, and why it deserves an honest conversation
Here is a thread that runs through everything above and is worth pulling on directly.
If the muscle you lose is difficult or impossible to rebuild, if the bone density that quietly erodes is not easily recovered, if the hormonal infrastructure around fat regulation, leptin signalling, and IGF-1 production is disrupted in ways that persist after the drug stops, then what you are left with is a body that may function less well without the drug than it did before you started it.
This is not a hypothetical concern. Studies consistently show that when people stop GLP-1 drugs, appetite returns and weight comes back, often substantially, within a year. Some of this is simply the biology of obesity reasserting itself. But some of it may also reflect the fact that the underlying metabolic infrastructure, the muscle mass, the hormonal balance, the insulin sensitivity, has been altered in ways that make the body more dependent on the pharmacological override rather than less.
For people who genuinely need long-term medical management of obesity or type 2 diabetes, ongoing treatment may be entirely appropriate and worth it. That is a conversation for a physician to have with a patient based on their full picture.
The concern is for the much larger group of people who will start these drugs casually, without proper assessment, without a plan, and without understanding that the exit may be harder than the entry.
Why the slow road still makes sense for most people
For the majority of people, thinking about these drugs not because of a serious medical condition but because they would like to lose weight, the fundamentals still offer something that no drug currently can.
A modest, sustained caloric deficit allows hunger hormones to recalibrate gradually. Resistance training builds and preserves muscle, improves insulin sensitivity, and maintains the metabolic infrastructure that keeps you healthy long after the workout ends. Sleep and stress management regulate cortisol, which directly influences where the body stores fat and how well it recovers. These are not romantic ideas. They are the things that change the underlying system rather than temporarily override it.
The slow road is slow. It is not Instagram-worthy. But what it builds tends to stay built.
So where does this leave us?
GLP-1 drugs are a genuine medical advance. For people who need serious intervention, they offer something real, and the evidence behind them is substantial. The question India needs to answer as these generics arrive is not whether the drugs work. It is whether we will use them thoughtfully.
The antibiotic story should give us pause. Not because the situations are identical, but because they share a pattern. A powerful tool, made cheaply available, used without adequate information or supervision, in a country where the line between a prescription drug and a purchase decision is often thinner than it should be.
These drugs deserve better than a WhatsApp forward. The person considering them deserves a real conversation with a qualified doctor who can look at their full picture. Their age, body composition, metabolic markers, existing conditions, lifestyle, and a plan that covers not just starting the medication but what happens throughout and after, including what it takes to preserve muscle, protect bone, maintain hormonal balance, and build a life that does not depend indefinitely on pharmacological support.
If that sounds like more effort than ordering a generic online, it is.